New Amsterdam Genomics (NAG) was started in 2010 by Andrew Mills, and is headquartered in Manhattan, New York. From disease prevention, risk assessment, and patient education, to cancer research and treatment, genomics stands to make healthcare a completely personalized experience. NAG wants to empower each patient and their physician with the power of genomic data, and has lead the charge by developing a genomic analysis platform and suite of computational algorithms that determine the impact a person’s genome has on their health and well-being, all delivered through a point-of-care tool designed for clinical use.